Asymmetric Ruthenium Complex Synthesis via One-Pot Imidazolium Salt Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The synthesis of asymmetric 1,3-disubstituted diaminocarbene imidazolin-2-ylidene ligands is complex and not industrially competitive due to the high number of chemical operations required and limited choice of non-identical carbon-containing substituent groups, particularly lacking methods for N-heterocyclic diaminocarbene ligands of the 1-aryl-3-cycloalkyl-imidazolin-2-ylidene type.
Innovation Solution
The development of an alkylidene ruthenium complex with a 1-aryl-3-cycloalkyl-imidazolin-2-ylidene ligand, where the cycloalkyl group is a cyclic secondary aliphatic alkyl, and a method for synthesizing this complex involving the formation of an asymmetric imidazolium salt using a single chemical operation, followed by reaction with a ruthenium complex precursor and a strong base under inert conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If asymmetric 1,3-disubstituted diaminocarbene imidazolin-2-ylidene ligands are synthesized using conventional methods, then the ligands can be obtained with desired structural diversity, but the synthesis requires a very large number of chemical operations (4 to 6 separate operations) making it complex and not industrially competitive
Solution Approach 1:
The patent combines multiple separate chemical operations into a single one-pot procedure. The synthesis integrates formylation, condensation, and cyclization steps that were previously performed separately (4-6 operations) into a single operational sequence, thereby reducing procedural complexity while maintaining structural diversity of asymmetric ligands
Solution Approach 2:
The patent employs preliminary action by pre-forming the imidazolium salt intermediate with the desired asymmetric substitution pattern before the final carbene generation step. This allows the complex asymmetric structure to be established early in the sequence, simplifying subsequent steps and enabling industrial scalability
2Adaptability or versatility
If asymmetric 1,3-disubstituted diaminocarbene imidazolin-2-ylidene ligands are synthesized using conventional methods, then certain carbon-containing substituent groups can be incorporated, but the choice of non-identical carbon-containing substituent groups is limited
Solution Approach 1:
The patent creates a universal synthetic platform that can accommodate diverse carbon-containing substituent groups (aromatic, aliphatic, heterocyclic, electron-rich, electron-poor) through a single multifunctional reaction protocol. The one-pot procedure serves multiple functions: it handles different substituent types, performs multiple transformations, and generates the final carbene product, thereby expanding substituent choice without proportionally increasing synthesis complexity
Solution Approach 2:
The patent utilizes parameter changes by adjusting reaction conditions (temperature, solvent, catalyst, stoichiometry) to accommodate different carbon-containing substituent groups. The flexible protocol allows optimization of parameters for specific substituent types, enabling broad applicability while maintaining ease of manufacture through systematic condition adjustment rather than developing separate synthesis routes for each substituent class
3Ease of manufacture
If symmetric 1,3-disubstituted diaminocarbene ligands are used in organometallic catalytic systems, then the synthesis is simpler and well-established, but the catalytic selectivity and reactivity are limited compared to asymmetric ligands
Solution Approach 1:
The patent applies asymmetry by designing and synthesizing asymmetric 1,3-disubstituted diaminocarbene ligands where the two substituents at positions 1 and 3 are different (e.g., aromatic vs. aliphatic, electron-rich vs. electron-poor). This asymmetric structure creates chiral environments around the metal center, enhancing catalytic selectivity and reactivity for specific transformations while maintaining practical synthesis through the streamlined one-pot procedure
Data Source
AI summary
The invention relates to a ruthenium alkylidene complex comprising a 1-aryl-3-cycloalkyl-imidazolin-2-ylidene ligand, the cycloalkyl group of said 1-aryl-3-cycloalkyl-imidazolin-2-ylidene ligand being a cyclic secondary aliphatic alkyl.